Trabectedin and RAdiotherapy in So ... | Article | H1 Connect
[Clinical Trial: Non-RCT]
Gronchi A et al.
EClinicalMedicine. 2019 Mar; 9:35-43
https://doi.org/10.1016/j.eclinm.2019.03.007PMID: 31143880Evaluations
A phase II trial is underway exploring multimodality therapy with trabectedin and radiation therapy for patients with localized myxoid liposarcoma (MLPS). This phase I study showed an acceptable safety profile for this approach.
This Recommendation is of an article referenced in a Faculty Review also written by Richard Riedel.
Relevant Specialties
Oncology
Oncologic Drugs | Sarcomas
Clinical Trials
- Trial registry title:
- Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Identifier:
- NCT02275286
- Grupo Espanol de Investigacion en Sarcomas Phase:
- Phase 1/Phase 2 Gender:
- All Min Age:
- 18 Years Max Age:
- N/A Conditions:
- Liposarcoma, Myxoid, Sarcoma, Soft Tissue, Leiomyosarcoma, Liposarcoma, Pleomorphic Liposarcoma Interventions:
- Trabectedin, Radiotherapy Countries:
- France, Italy, Spain Official Title:
- Phase I-II Prospective Trial, Multicenter, Open Label, Exploring the Combination of Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
Sponsor: